Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Compliance Strategy: Meetings Replace Some Untitled Letters

Executive Summary

FDA’s CDER compliance office may use in-person meetings instead of untitled letters to avoid bureaucratic delays when raising minor concerns.

Advertisement

Related Content

US FDA’s New Compliance Chief Donald Ashley Brings International Law Enforcement Experience
Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
FDA’s Untitled Letter Posting Driven By ‘Significant Public Interest,’ Not Stock Market
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Biosimilar User Fee Meeting Schedule Allows FDA Data “Pre-Review”

Topics

Advertisement
UsernamePublicRestriction

Register

PS119657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel